Evidence map›Paper›PMID 21221855›Full record

ReviewCurrent HIV/AIDS reports2011

HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies.

Eva A Operskalski, Andrea Kovacs

Registry-linked trialOpen access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current HIV/AIDS reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03163849 (Assessment of Haematological and Biochemical Effect After New Direct Acting Antiviral Drugs in Chronic Hepatitis c Virus Egyptian Patients in Assiut Province), which is not on this map. Cited by 101 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 8 pooled it
12.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03163849 phase3unknown statusnot on this mapstarted 2019, after this paper: background citation

Assessment of Haematological and Biochemical Effect After New Direct Acting Antiviral Drugs in Chronic Hepatitis c Virus Egyptian Patients in Assiut Province

TypeinterventionalSponsorAssiut UniversityRan2019 to 2020Enrolled50ConditionsChronic Hepatitis cArmsSofosbuvir , daclatasvir, Placebos
3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 8 syntheses or guidelines pooled it, 217 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018
    Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. A spotlight on HCV and SARS-CoV-2 co-infection and brain function.Pharmacology, biochemistry, and behavior · 2022
    Article

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Eva A OperskalskiMaternal Child and Adolescent Center for Infectious Diseases and Virology, Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, 90033, USA. eva@usc.edu
Andrea Kovacs
University of Southern California · US

Funding

HCV and Progression of HIV and HAART Response in WomenR01AI052065 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KOVACS, ANDREA A.Z. · 2002 to 2011
$6.9M
HIV AND HCV DISEASE PROGRESSION IN WOMEN ON HAARTR56AI052065 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KOVACS, ANDREA A.Z. · 2014 to 2014
$655k
NIAID NIH HHS 2 R01 AI 052065-05A2NIAID NIH HHS R01 AI052065NIAID NIH HHS R56 AI052065
6 · The paper itself

Abstract

World-wide, hepatitis C virus (HCV) accounts for approximately 130 million chronic infections, with an overall 3% prevalence. Four to 5 million persons are co-infected with HIV. It is well established that HIV has a negative impact on the natural history of HCV, including a higher rate of viral persistence, increased viral load, and more rapid progression to fibrosis, end-stage liver disease, and death. Whether HCV has a negative impact on HIV disease progression continues to be debated. However, following the introduction of effective combination antiretroviral therapy, the survival of coinfected individuals has significantly improved and HCV-associated diseases have emerged as the most important co-morbidities. In this review, we summarize the newest studies regarding the pathogenesis of HIV/HCV coinfection, including effects of coinfection on HIV disease progression, HCV-associated liver disease, the immune system, kidney and cardiovascular disease, and neurologic status; and effectiveness of current anti-HIV and HCV therapies and proposed new treatment strategies.

Indexed as

Antiretroviral Therapy, Highly ActiveAntiviral AgentsDrug Therapy, CombinationHepacivirusHepatitis C, ChronicHIVHIV InfectionsHumansPrevalenceRandomized Controlled Trials as TopicRibavirinAntiviral AgentsRibavirin

Identifiers

PMID21221855
PMCPMC3035774
OpenAlexW2018253571

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.